AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20144471 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted surgical staging
Number of subjects: 275
Study 20144471 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic surgical staging
Number of subjects: 275
Study 17625432 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (200 mg/day, orally)
Number of subjects: 267
Study 17625432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 15831782 — intervention group
Group type: EXPERIMENTAL
Intervention: R1518 (levovirin valinate hydrochloride)
Number of subjects: 0
Study 27398636 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy
Number of subjects: 59
Study 27398636 — intervention group
Group type: COMPARATOR
Intervention: 123I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-CIT) SPECT
Number of subjects: 59
Study 11197445 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/day)
Number of subjects: 4495
Study 11197445 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg/day)
Number of subjects: 4495
Study 9552780 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (6 microg/kg/h)
Number of subjects: 28
Study 9552780 — intervention group
Group type: COMPARATOR
Intervention: Propofol (3 mg/kg/h)
Number of subjects: 28
Study 7871917 — intervention group
Group type: EXPERIMENTAL
Intervention: Credé-prophylaxis with Argentum nitricum
Number of subjects: 40
Study 7871917 — intervention group
Group type: COMPARATOR
Intervention: No Credé-prophylaxis
Number of subjects: 40
Study 3421279 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal vitamin K1 (10 mg intramuscularly every 5 days until delivery)
Number of subjects: 92
Study 3421279 — intervention group
Group type: COMPARATOR
Intervention: No antenatal vitamin K1 therapy
Number of subjects: 92
Study 31138165 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based multimedia intervention including PowerPoint presentation, video clip, and health information booklet.
Number of subjects: 320
Study 31138165 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group receiving the intervention after post-intervention data collection.
Number of subjects: 320
Study 28696135 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution Focused Brief Therapy (SFBT)
Number of subjects: 62
Study 28696135 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychotherapy)
Number of subjects: 62
Study 25855751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-for-reporting intervention with monthly incentive fees and chart audits every 6 months.
Number of subjects: 11
Study 25855751 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 11
Study 22895620 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory self-efficacy (MSE) training program
Number of subjects: 153
Study 22895620 — intervention group
Group type: COMPARATOR
Intervention: Peer support program (control group)
Number of subjects: 153
Study 21970511 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior intervention (SB-I)
Number of subjects: 600
Study 21970511 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (PA-I)
Number of subjects: 600
Study 21970511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sedentary behavior and physical activity intervention (SB+PA-I)
Number of subjects: 600
Study 21970511 — intervention group
Group type: COMPARATOR
Intervention: Current practice control (C)
Number of subjects: 600
Study 18394088 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 16537663 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5 mg daily)
Number of subjects: 20078
Study 16537663 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (1 mg per kilogram of body weight twice daily)
Number of subjects: 20078
Study 16537663 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 20078
Study 16537663 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 20078
Study 12773061 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO 1000 units/kg
Number of subjects: 0
Study 12773061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11043855 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphonylureas
Number of subjects: 22
Study 11043855 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 22
Study 11043855 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 22
Study 9358570 — intervention group
Group type: EXPERIMENTAL
Intervention: Coelocentesis
Number of subjects: 20
Study 9358570 — intervention group
Group type: COMPARATOR
Intervention: Control group (planned termination)
Number of subjects: 20
Study 8129540 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg + Nifedipine 20 mg (AN)
Number of subjects: 57
Study 8129540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 57
Study 3524837 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) at total doses less than 902 mg/m2
Number of subjects: 289
Study 3524837 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) at total doses greater than 902 mg/m2
Number of subjects: 289
Study 3524837 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU) at total doses exceeding 1400 mg/m2
Number of subjects: 289
Study 3524837 — intervention group
Group type: COMPARATOR
Intervention: Misonidazole administration
Number of subjects: 289
Study 31301031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 60
Study 29806405 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-subvastus approach
Number of subjects: 94
Study 29806405 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 94
Study 29806405 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 94
Study 26514145 — intervention group
Group type: EXPERIMENTAL
Intervention: ALFIT training (8-week equipment-based progressive resistance training program)
Number of subjects: 38
Study 26514145 — intervention group
Group type: COMPARATOR
Intervention: Routine program of the day hospital (Control group)
Number of subjects: 38
Study 25131034 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapeutic program including diaphragmatic breathing exercises, diaphragmatic isometric exercise, Threshold IMT, lifting the upper limbs with a bat, and strengthening the abdominals
Number of subjects: 42
Study 25131034 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 42
Study 22316106 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 2269
Study 22316106 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 2269
Study 22316106 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (200 mg or 300 mg depending on renal function)
Number of subjects: 2269
Study 20649528 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume/low concentration solution of ropivacaine (20 ml, 0.5%)
Number of subjects: 48
Study 20649528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume/high concentration solution of ropivacaine (10 ml, 1%)
Number of subjects: 48
Study 20649528 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume/low concentration group
Number of subjects: 48
Study 20649528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low volume/high concentration group
Number of subjects: 48
Study 20649528 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Number of subjects: 48
Study 17983398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up (n=58) including diagnostic laboratory tests and imaging.
Number of subjects: 121
Study 17983398 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical follow-up (n=63) with annual mammography.
Number of subjects: 121
Study 17983398 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical follow-up (n=63)
Number of subjects: 121
Study 17983398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up (n=58)
Number of subjects: 121
Study 15991756 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-guided education and monitoring (PGEM) through three monthly telephone calls
Number of subjects: 63
Study 15991756 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmacist's care
Number of subjects: 63
Study 12509594 — intervention group
Group type: EXPERIMENTAL
Intervention: SpO2 of 94% and RR of 50/min
Number of subjects: 519
Study 12509594 — intervention group
Group type: EXPERIMENTAL
Intervention: SpO2 of 94% and RR of 65/min
Number of subjects: 519
Study 12509594 — intervention group
Group type: EXPERIMENTAL
Intervention: SpO2 of 92% and RR of 50/min
Number of subjects: 519
Study 12509594 — intervention group
Group type: EXPERIMENTAL
Intervention: SpO2 of 92% and RR of 65/min
Number of subjects: 519
Study 11221808 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (6-week guided training in hospital, followed by 6 weeks at home, and 12 weeks at home without supervision)
Number of subjects: 58
Study 11221808 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 58
Study 7852918 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood donations (venesection)
Number of subjects: 14
Study 7852918 — intervention group
Group type: COMPARATOR
Intervention: Control (no blood donations)
Number of subjects: 14
Study 1777051 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol CR
Number of subjects: 83
Study 1777051 — intervention group
Group type: COMPARATOR
Intervention: Theophylline L.A.
Number of subjects: 83
Study 7143496 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane casts
Number of subjects: 46
Study 7143496 — intervention group
Group type: COMPARATOR
Intervention: Plaster-of-Paris braces
Number of subjects: 46
Study 6362597 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune globulin (0.06 mL/kg of body weight)
Number of subjects: 60
Study 6362597 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (0.06 mL/kg of body weight)
Number of subjects: 60
Study 6362597 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune globulin (twice the dose of the first group)
Number of subjects: 60
Study 28460586 — intervention group
Group type: EXPERIMENTAL
Intervention: [6S]-5-methyltetrahydrofolate (400 μg/d)
Number of subjects: 40
Study 28460586 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (400 μg/d)
Number of subjects: 40
Study 27525386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (140 mg/day)
Number of subjects: 330
Study 27525386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 25407792 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet using olive oil
Number of subjects: 24
Study 25407792 — intervention group
Group type: COMPARATOR
Intervention: Control low-fat diet
Number of subjects: 24
Study 22849308 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL/kg IV fluid administration
Number of subjects: 42
Study 22849308 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL/kg IV fluid administration
Number of subjects: 42
Study 22849308 — intervention group
Group type: COMPARATOR
Intervention: 2 mL/kg IV fluid administration (control group)
Number of subjects: 42
Study 20705558 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy plus zoledronic acid
Number of subjects: 0
Study 20705558 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 0
Study 18502360 — intervention group
Group type: COMPARATOR
Intervention: 0.0 mg intrathecal morphine (Control)
Number of subjects: 100
Study 18502360 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg intrathecal morphine
Number of subjects: 100
Study 18502360 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg intrathecal morphine
Number of subjects: 100
Study 18502360 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg intrathecal morphine
Number of subjects: 100
Study 18502360 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg intrathecal morphine
Number of subjects: 100
Study 18502360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.1 to 0.4 mg)
Number of subjects: 100
Study 15985482 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-yr low-energy diet
Number of subjects: 150
Study 11443511 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg HCA
Number of subjects: 11
Study 11443511 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg HCA and 3 g MCT
Number of subjects: 11
Study 11443511 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (PLA)
Number of subjects: 11
Study 11443511 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (PLA, HCA, HCA+MCT)
Number of subjects: 11
Study 9778328 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa + estrogen/progestogen add-back therapy
Number of subjects: 2
Study 9778328 — intervention group
Group type: COMPARATOR
Intervention: GnRHa alone
Number of subjects: 2
Study 7820145 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO by subcutaneous route, initial doses of 20U/kg/dialysis, mean correction dose of 65U/kg/dialysis, maintenance dose of 51U/kg/dialysis
Number of subjects: 12
Study 2458159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 40
Study 2458159 — intervention group
Group type: COMPARATOR
Intervention: Plasma protein fraction (PPF)
Number of subjects: 40
Study 29949492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticoid plus LABA (combination therapy)
Number of subjects: 36010
Study 29949492 — intervention group
Group type: COMPARATOR
Intervention: Inhaled glucocorticoid alone (control)
Number of subjects: 36010
Study 26549852 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced psychosocial support (counseling and psychosocial interventions by a palliative care nurse and social worker)
Number of subjects: 29
Study 26549852 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced psychosocial support
Number of subjects: 29
Study 26549852 — intervention group
Group type: COMPARATOR
Intervention: Standard renal care (control)
Number of subjects: 29
Study 25282874 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD), skin care, bandaging, and remedial exercises
Number of subjects: 57
Study 25282874 — intervention group
Group type: COMPARATOR
Intervention: Skin care, bandaging, and remedial exercises
Number of subjects: 57
Study 25282874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (MLD and control)
Number of subjects: 57
Study 22819803 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 48
Study 22819803 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg taurine
Number of subjects: 48
Study 22819803 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 48
Study 22819803 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine + 50 g glucose
Number of subjects: 48
Study 22819803 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 mg taurine + 50 g glucose
Number of subjects: 48
Study 22819803 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol and heart rate
Number of subjects: 48
Study 22128442 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac-cholestyramine + uridine + cytidine + vitamin B12 (Group DN)
Number of subjects: 81
Study 22128442 — intervention group
Group type: COMPARATOR
Intervention: uridine + cytidine + vitamin B12 (Group NB)
Number of subjects: 81
Study 22128442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study 17493196 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN 70 mg once a week plus calcitriol (1,25D3) 0.5 microg daily
Number of subjects: 120
Study 17493196 — intervention group
Group type: COMPARATOR
Intervention: ALN 70 mg once a week alone
Number of subjects: 120
Study 17493196 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ALN alone and ALN plus calcitriol)
Number of subjects: 120
Study 15664872 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteotomy by sawing
Number of subjects: 80
Study 15664872 — intervention group
Group type: COMPARATOR
Intervention: Osteotomy by milling
Number of subjects: 80
Study 12198013 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (0.5 mmol.kg(-1).d(-1))
Number of subjects: 16
Study 12198013 — intervention group
Group type: COMPARATOR
Intervention: Control group (alanine)
Number of subjects: 16
Study 9609267 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol (2 mg daily) for 20 to 24 weeks
Number of subjects: 28
Study 9609267 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 20 to 24 weeks
Number of subjects: 28
Study 7639104 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous 17‐beta‐estradiol (50 micrograms daily)
Number of subjects: 124
Study 7639104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical intravenous clodronate (200 mg/month iv infusion)
Number of subjects: 124
Study 7639104 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 124
Study 2560289 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (duration: 6 months)
Number of subjects: 201
Study 2560289 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls (no treatment)
Number of subjects: 201
Study 791563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) at doses of 0, 150, or 500 mug/kg
Number of subjects: 6
Study 791563 — intervention group
Group type: COMPARATOR
Intervention: Secobarbital (150 mg/70 kg)
Number of subjects: 6
Study 791563 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital (150 mg/70 kg) with CBD pretreatment
Number of subjects: 6
Study 31770194 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with LED (660 and 850 nm with 6 J per point for extraoral device; 660 nm with 2 J per point for intraoral device)
Number of subjects: 72
Study 31770194 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulated irradiation with devices kept off)
Number of subjects: 72
Study 31770194 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with LED
Number of subjects: 72
Study 29513547 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded condition (valgus load)
Number of subjects: 22
Study 29513547 — intervention group
Group type: COMPARATOR
Intervention: Unloaded condition (at rest)
Number of subjects: 22
Study 29513547 — intervention group
Group type: EXPERIMENTAL
Intervention: Loaded-contracted condition (maximal grip contraction under valgus load)
Number of subjects: 22
Study 26729384 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on inhaler technique and adherence from the audio recording device over a 3-month period.
Number of subjects: 220
Study 26729384 — intervention group
Group type: COMPARATOR
Intervention: Training in inhaler technique and strategies to promote adherence (no feedback from the device).
Number of subjects: 220
Study 24368554 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 16
Study 24368554 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 16
Study 22221171 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (45 mg daily)
Number of subjects: 24
Study 22221171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20638340 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (37.5 mg intravenous administration before embryo transfer)
Number of subjects: 180
Study 20638340 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 180
Study 20638340 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 180
Study 17596728 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Depression Scale (GDS-15)
Number of subjects: 62
Study 17596728 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 62
Study 16334434 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 93
Study 16334434 — intervention group
Group type: COMPARATOR
Intervention: Open fundoplication (Laparotomy)
Number of subjects: 93
Study 11926622 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-time peak expiratory flow rate (PEFR) monitoring
Number of subjects: 168
Study 11926622 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PEFR monitoring
Number of subjects: 168
Study 11926622 — intervention group
Group type: COMPARATOR
Intervention: Subjective symptom evaluation
Number of subjects: 168
Study 10406235 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 408
Study 10406235 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg
Number of subjects: 408
Study 10406235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study 8525691 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombivax 10 micrograms
Number of subjects: 346
Study 8525691 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombivax 5 micrograms
Number of subjects: 346
Study 8525691 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix 10 micrograms
Number of subjects: 346
Study 8525691 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix 5 micrograms
Number of subjects: 346
Study 2265160 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine (8.25% dextrose)
Number of subjects: 22
Study 2265160 — intervention group
Group type: COMPARATOR
Intervention: 1% tetracaine mixed with an equal volume of 10% procaine
Number of subjects: 22
Study 455950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 0
Study 455950 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study 455950 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonscheduled therapy
Number of subjects: 0
Study 455950 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of psychotherapy and pharmacotherapy
Number of subjects: 0
Study 31832721 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 69